{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:09Z","timestamp":1789609089787,"version":"build-2803163510"},"reference-count":146,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.transci.2021.103164","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T17:05:20Z","timestamp":1621616720000},"page":"103164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Emerging insights into the role of albumin with plasma exchange in Alzheimer\u2019s disease management"],"prefix":"10.1016","volume":"60","author":[{"given":"Montserrat","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"P\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2021.103164_bib0005","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.transci.2021.103164_bib0010","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1212\/WNL.0b013e3181d3e3e9","article-title":"Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB","volume":"74","author":"Resnick","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.transci.2021.103164_bib0015","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1212\/WNL.0b013e3181f39adc","article-title":"Neurodegenerative basis of age-related cognitive decline","volume":"75","author":"Wilson","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.transci.2021.103164_bib0020","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1212\/WNL.0000000000000650","article-title":"Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology","volume":"83","author":"Monsell","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.transci.2021.103164_bib0025","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.transci.2021.103164_bib0030","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.22248","article-title":"Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease","volume":"69","author":"Villemagne","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.transci.2021.103164_bib0035","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.nrl.2016.02.016","article-title":"Prevalence and incidence of Alzheimer\u2019s disease in Europe: a meta-analysis","volume":"32","author":"Niu","year":"2017","journal-title":"Neurologia"},{"key":"10.1016\/j.transci.2021.103164_bib0040","first-page":"391","article-title":"Alzheimer\u2019s disease facts and figures","volume":"16","author":"Alzheimer\u2019s Association Report","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.transci.2021.103164_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","article-title":"National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach","volume":"123","author":"Montine","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.transci.2021.103164_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.transci.2021.103164_bib0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1750-3639.1991.tb00661.x","article-title":"Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections","volume":"1","author":"Braak","year":"1991","journal-title":"Brain Pathol"},{"key":"10.1016\/j.transci.2021.103164_bib0060","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0196-9781(02)00070-0","article-title":"Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins","volume":"23","author":"Atwood","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.transci.2021.103164_bib0065","doi-asserted-by":"crossref","first-page":"e64971","DOI":"10.1371\/journal.pone.0064971","article-title":"Inflammatory proteins in plasma are associated with severity of Alzheimer\u2019s disease","volume":"8","author":"Leung","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.transci.2021.103164_bib0070","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3233\/JAD-170732","article-title":"A long journey into aging, brain aging, and Alzheimer\u2019s disease following the oxidative stress tracks","volume":"62","author":"Mecocci","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0075","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/jnen\/60.8.759","article-title":"Oxidative damage is the earliest event in Alzheimer disease","volume":"60","author":"Nunomura","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.transci.2021.103164_bib0080","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.transci.2021.103164_bib0085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/nbdi.1996.0003","article-title":"Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation","volume":"3","author":"Lemere","year":"1996","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0090","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/nm1096-1146","article-title":"The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology","volume":"2","author":"Lemere","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.transci.2021.103164_bib0095","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2021.103164_bib0100","doi-asserted-by":"crossref","first-page":"e31302","DOI":"10.1371\/journal.pone.0031302","article-title":"Trans-synaptic spread of tau pathology in vivo","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.transci.2021.103164_bib0105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/alzrt214","article-title":"Propagation of tau pathology in Alzheimer\u2019s disease: identification of novel therapeutic targets","volume":"5","author":"Pooler","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.transci.2021.103164_bib0110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1590\/S1980-57642009DN30300003","article-title":"Neurobiological pathways to Alzheimer\u2019s disease: Amyloid-beta, TAU protein or both?","volume":"3","author":"de Paula","year":"2009","journal-title":"Dement Neuropsychol"},{"key":"10.1016\/j.transci.2021.103164_bib0115","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.neuron.2008.11.007","article-title":"Linking Abeta and tau in late-onset Alzheimer\u2019s disease: a dual pathway hypothesis","volume":"60","author":"Small","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.transci.2021.103164_bib0120","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","article-title":"Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins","volume":"95","author":"Lambert","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.transci.2021.103164_bib0125","doi-asserted-by":"crossref","first-page":"S567","DOI":"10.3233\/JAD-179941","article-title":"The amyloid-beta oligomer hypothesis: beginning of the third decade","volume":"64","author":"Cline","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0130","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1073\/pnas.222681699","article-title":"Amyloid beta -protein (Abeta) assembly: abeta 40 and Abeta 42 oligomerize through distinct pathways","volume":"100","author":"Bitan","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.transci.2021.103164_bib0135","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3233\/JAD-2010-1221","article-title":"Alzheimer\u2019s Disease and the \u03b2-Amyloid Peptide","volume":"19","author":"Murphy","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0140","first-page":"5","article-title":"American Psychiatric Association practice guideline for the treatment of patients with Alzheimer\u2019s disease and other dementias","volume":"164","author":"Rabins","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.transci.2021.103164_bib0145","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1468-1331.2010.03040.x","article-title":"EFNS guidelines for the diagnosis and management of Alzheimer\u2019s disease","volume":"17","author":"Hort","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.transci.2021.103164_bib0150","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/ene.12707","article-title":"EFNS-ENS\/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer\u2019s disease","volume":"22","author":"Schmidt","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.transci.2021.103164_bib0155","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","article-title":"Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer\u2019s disease progression","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Res"},{"key":"10.1016\/j.transci.2021.103164_bib0160","doi-asserted-by":"crossref","first-page":"218980","DOI":"10.1155\/2015\/218980","article-title":"Nonpharmacological interventions to reduce behavioral and psychological symptoms of dementia: a systematic review","volume":"2015","author":"de Oliveira","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.transci.2021.103164_bib0165","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3233\/JAD-132690","article-title":"Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"41","author":"Tan","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0170","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/JAD-122140","article-title":"A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer\u2019s disease","volume":"35","author":"Di Santo","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0175","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/2040622312452387","article-title":"Management of patients with Alzheimer\u2019s disease: pharmacological treatment and quality of life","volume":"3","author":"Mossello","year":"2012","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0180","series-title":"Update on phase III clinical trials of lanabecestat for Alzheimer\u2019s disease, Cision PR newswire","author":"AstraZeneca","year":"2018"},{"key":"10.1016\/j.transci.2021.103164_bib0185","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of verubecestat for mild-to-Moderate alzheimer\u2019s disease","volume":"378","author":"Egan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2021.103164_bib0190","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease","volume":"380","author":"Egan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2021.103164_bib0195","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMc1813435","article-title":"Preliminary results of a trial of atabecestat in preclinical Alzheimer\u2019s disease","volume":"380","author":"Henley","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2021.103164_bib0200","series-title":"Novartis, Amgen and Banner Alzheimer\u2019s Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer\u2019s prevention","author":"Ligi","year":"2019"},{"key":"10.1016\/j.transci.2021.103164_bib0205","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.transci.2021.103164_bib0210","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late-stage drug development for Alzheimer\u2019s disease: an appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"J Intern Med"},{"key":"10.1016\/j.transci.2021.103164_bib0215","series-title":"Biogen and Eisai to discontinue phase 3 engage and emerge trials of aducanumab in Alzheimer\u2019s disease","author":"Biogen","year":"2019"},{"key":"10.1016\/j.transci.2021.103164_bib0220","series-title":"Biogen plans regulatory filing for aducanumab in Alzheimer\u2019s disease based on new analysis of larger dataset from phase 3 studies","author":"Biogen","year":"2019"},{"key":"10.1016\/j.transci.2021.103164_bib0225","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jalz.2019.09.075","article-title":"The path forward in Alzheimer\u2019s disease therapeutics: reevaluating the amyloid cascade hypothesis","volume":"16","author":"Tolar","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.transci.2021.103164_bib0230","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1006\/bbrc.2000.2222","article-title":"Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma","volume":"268","author":"Kuo","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"issue":"Suppl 2","key":"10.1016\/j.transci.2021.103164_bib0235","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3233\/JAD-2011-102139","article-title":"Amyloid clearance as a treatment target against Alzheimer\u2019s disease","volume":"24","author":"Kurz","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0240","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/156720507780362245","article-title":"Role of the blood-brain barrier in the pathogenesis of Alzheimer\u2019s disease","volume":"4","author":"Deane","year":"2007","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.transci.2021.103164_bib0245","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1248\/bpb.32.527","article-title":"Pharmaceutically important pre- and posttranslational modifications on human serum albumin","volume":"32","author":"Otagiri","year":"2009","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.transci.2021.103164_bib0250","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.mam.2011.12.002","article-title":"Human serum albumin: from bench to bedside","volume":"33","author":"Fanali","year":"2012","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.transci.2021.103164_bib0255","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/1869","article-title":"Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites","volume":"5","author":"Curry","year":"1998","journal-title":"Nat Struct Biol"},{"issue":"Suppl 5","key":"10.1016\/j.transci.2021.103164_bib0260","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2036.16.s5.2.x","article-title":"Review article: albumin as a drug--biological effects of albumin unrelated to oncotic pressure","volume":"16","author":"Evans","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.transci.2021.103164_bib0265","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1042\/cs0950459","article-title":"Administration of albumin to patients with sepsis syndrome: a possible beneficial role in plasma thiol repletion","volume":"95","author":"Quinlan","year":"1998","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.transci.2021.103164_bib0270","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/prca.200780040","article-title":"Clinical proteomics of the cerebrospinal fluid: towards the discovery of new biomarkers","volume":"2","author":"Roche","year":"2008","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.transci.2021.103164_bib0275","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1570-0232(02)00114-9","article-title":"Database of bronchoalveolar lavage fluid proteins","volume":"771","author":"No\u00ebl-Georis","year":"2002","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.transci.2021.103164_bib0280","series-title":"Arthritis and allied conditions: a textbook of rheumatology","first-page":"81","article-title":"Synovial fluid","author":"McCarty","year":"1997"},{"key":"10.1016\/j.transci.2021.103164_bib0285","series-title":"All about albumin","first-page":"9","article-title":"The albumin molecule: its structure and chemical properties","author":"Peters","year":"1995"},{"key":"10.1016\/j.transci.2021.103164_bib0290","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0065-3233(08)60065-0","article-title":"Serum albumin","volume":"37","author":"Peters","year":"1985","journal-title":"Adv Protein Chem"},{"key":"10.1016\/j.transci.2021.103164_bib0295","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0065-3233(08)60640-3","article-title":"Structure of serum albumin","volume":"45","author":"Carter","year":"1994","journal-title":"Adv Protein Chem"},{"key":"10.1016\/j.transci.2021.103164_bib0300","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0031-6997(25)06849-8","article-title":"Molecular aspects of ligand binding to serum albumin","volume":"33","author":"Kragh-Hansen","year":"1981","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.transci.2021.103164_bib0305","series-title":"All about albumin","first-page":"76","article-title":"Ligand binding by albumin","author":"Peters","year":"1995"},{"key":"10.1016\/j.transci.2021.103164_bib0310","doi-asserted-by":"crossref","first-page":"32916","DOI":"10.1074\/jbc.271.51.32916","article-title":"Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma","volume":"271","author":"Biere","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.transci.2021.103164_bib0315","doi-asserted-by":"crossref","first-page":"28163","DOI":"10.1074\/jbc.C112.360800","article-title":"Human serum albumin can regulate amyloid-\u03b2 peptide fiber growth in the brain interstitium: implications for Alzheimer disease","volume":"287","author":"Stanyon","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.transci.2021.103164_bib0320","doi-asserted-by":"crossref","first-page":"15990","DOI":"10.1074\/jbc.274.23.15990","article-title":"Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues","volume":"274","author":"Bohrmann","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.transci.2021.103164_bib0325","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.bpj.2009.08.028","article-title":"Human serum albumin inhibits Abeta fibrillization through a \"monomer-competitor\" mechanism","volume":"97","author":"Milojevic","year":"2009","journal-title":"Biophys J"},{"key":"10.1016\/j.transci.2021.103164_bib0330","doi-asserted-by":"crossref","first-page":"e2829","DOI":"10.1371\/journal.pone.0002829","article-title":"Human microglial cells synthesize albumin in brain","volume":"3","author":"Ahn","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.transci.2021.103164_bib0335","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1089\/ars.2012.4702","article-title":"Redox albuminomics: oxidized albumin in human diseases","volume":"17","author":"Colombo","year":"2012","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.transci.2021.103164_bib0340","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1006\/bbrc.1996.0793","article-title":"Glutathione-linked thiol peroxidase activity of human serum albumin: a possible antioxidant role of serum albumin in blood plasma","volume":"222","author":"Cha","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.transci.2021.103164_bib0345","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10384-010-0877-y","article-title":"Difference in redox status of serum and aqueous humor in senile cataract patients as monitored via the albumin thiol-redox state","volume":"54","author":"Kawai","year":"2010","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.transci.2021.103164_bib0350","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2110-5820-3-4","article-title":"Specific antioxidant properties of human serum albumin","volume":"3","author":"Taverna","year":"2013","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.transci.2021.103164_bib0355","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.febslet.2008.04.057","article-title":"The antioxidant properties of serum albumin","volume":"582","author":"Roche","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1016\/j.transci.2021.103164_bib0360","doi-asserted-by":"crossref","first-page":"C439","DOI":"10.1152\/ajpcell.1993.265.2.C439","article-title":"Albumin and Ricinus communis agglutinin decrease endothelial permeability via interactions with matrix","volume":"265","author":"Qiao","year":"1993","journal-title":"Am J Physiol"},{"key":"10.1016\/j.transci.2021.103164_bib0365","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0272-6386(99)70306-9","article-title":"Effect of increasing serum albumin on plasma D-dimer, von Willebrand factor, and platelet aggregation in CAPD patients","volume":"33","author":"Kim","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0370","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/09680519020080020501","article-title":"Investigation into the interaction of recombinant human serum albumin with Re-lipopolysaccharide and lipid A","volume":"8","author":"Jurgens","year":"2002","journal-title":"J Endotoxin Res"},{"key":"10.1016\/j.transci.2021.103164_bib0375","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1423-0410.2011.01475.x","article-title":"Immunomodulatory effects of therapeutic preparations of human albumin","volume":"101","author":"Aubin","year":"2011","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2021.103164_bib0380","first-page":"1","article-title":"The immunomodulatory effects of Albumin in vitro and in vivo","volume":"2011","author":"Wheeler","year":"2011","journal-title":"Adv Pharmacoll Sci"},{"key":"10.1016\/j.transci.2021.103164_bib0385","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax5135","article-title":"Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis","author":"Casulleras","year":"2020","journal-title":"Sci Translat Med"},{"key":"10.1016\/j.transci.2021.103164_bib0390","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/hep.20829","article-title":"A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis","volume":"42","author":"Fern\u00e1ndez","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.transci.2021.103164_bib0395","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0008-6363(02)00492-3","article-title":"Albumin selectively inhibits TNF alpha-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells","volume":"55","author":"Zhang","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.transci.2021.103164_bib0400","series-title":"Blood program in world war II","author":"Kendrick","year":"2020"},{"key":"10.1016\/j.transci.2021.103164_bib0405","first-page":"216","article-title":"Recommendations for the use of albumin and immunoglobulins","volume":"7","author":"Liumbruno","year":"2009","journal-title":"Blood Transfusion"},{"key":"10.1016\/j.transci.2021.103164_bib0410","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.3748\/wjg.v17.i30.3479","article-title":"How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure","volume":"17","author":"Mirici-Cappa","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.transci.2021.103164_bib0415","series-title":"All about albumin","first-page":"251","article-title":"Clinical aspects","author":"Peters","year":"1995"},{"key":"10.1016\/j.transci.2021.103164_bib0420","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1023\/A:1016120917510","article-title":"Evaluation of human albumin use in a university hospital in Belgium","volume":"24","author":"Somers","year":"2002","journal-title":"Pharm World Sci"},{"key":"10.1016\/j.transci.2021.103164_bib0425","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.26338","article-title":"Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications","volume":"58","author":"Garcia-Martinez","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.transci.2021.103164_bib0430","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/hep.22913","article-title":"Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality","volume":"50","author":"Jalan","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.transci.2021.103164_bib0435","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MEG.0b013e3280101f7d","article-title":"Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for end-stage liver disease","volume":"19","author":"Klammt","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.transci.2021.103164_bib0440","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jhep.2013.06.013","article-title":"Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival","volume":"59","author":"Oettl","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.transci.2021.103164_bib0445","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/00365520902719273","article-title":"Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"44","author":"Chen","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.transci.2021.103164_bib0450","doi-asserted-by":"crossref","DOI":"10.1111\/j.1530-0277.1996.tb01735.x","article-title":"Role of albumin and high-density lipoprotein as endotoxin-binding proteins in rats with acute and chronic alcohol loading","volume":"20","author":"Kitano","year":"1996","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.transci.2021.103164_bib0455","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/liv.12528","article-title":"Albumin infusion improves renal blood flow autoregulation in patients with acute decompensation of cirrhosis and acute kidney injury","volume":"35","author":"Garcia-Martinez","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.transci.2021.103164_bib0460","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nm.3516","article-title":"Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2","volume":"20","author":"O\u2019Brien","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.transci.2021.103164_bib0465","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2019.03.021","article-title":"Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis","volume":"157","author":"Fern\u00e1ndez","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.transci.2021.103164_bib0470","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa1305727","article-title":"Albumin replacement in patients with severe sepsis or septic shock","volume":"370","author":"Caironi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2021.103164_bib0475","doi-asserted-by":"crossref","first-page":"21530","DOI":"10.1074\/jbc.M112.372961","article-title":"Serum albumin prevents protein aggregation and amyloid formation and retains chaperone-like activity in the presence of physiological ligands","volume":"287","author":"Finn","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.transci.2021.103164_bib0480","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3233\/JAD-131169","article-title":"In vitro amyloid-beta binding and inhibition of amyloid-beta self-association by therapeutic albumin","volume":"38","author":"Milojevic","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0485","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3233\/JAD-2009-1093","article-title":"Albumin-blunted deleterious effect of amyloid-beta by preventing the internalization of the peptide into neurons","volume":"17","author":"Vega","year":"2009","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0490","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/JAD-160346","article-title":"Aberrant Co-localization of synaptic proteins promoted by Alzheimer\u2019s disease amyloid-beta peptides: protective effect of human serum albumin","volume":"55","author":"Dominguez-Prieto","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0495","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3233\/JAD-180332","article-title":"Endocytosis and transcytosis of Amyloid-\u03b2 peptides by astrocytes: a possible mechanism for amyloid-\u03b2 clearance in Alzheimer\u2019s disease","volume":"65","author":"Dom\u00ednguez-Prieto","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0500","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.csbj.2019.06.017","article-title":"Human albumin impairs amyloid beta-peptide fibrillation through its C-terminus: from docking modeling to protection against neurotoxicity in Alzheimer\u2019s disease","volume":"17","author":"Picon-Pages","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.transci.2021.103164_bib0505","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3233\/JAD-150694","article-title":"Multifunctional effect of human serum albumin reduces Alzheimer\u2019s disease related pathologies in the 3xTg mouse model","volume":"50","author":"Ezra","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"Suppl 1","key":"10.1016\/j.transci.2021.103164_bib0510","first-page":"S277","article-title":"The metal theory of Alzheimer\u2019s disease","volume":"33","author":"Bush","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0515","doi-asserted-by":"crossref","first-page":"15437","DOI":"10.1021\/jacs.7b08584","article-title":"Molecular insights into human serum albumin as a receptor of amyloid-\u03b2 in the extracellular region","volume":"139","author":"Choi","year":"2017","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.transci.2021.103164_bib0520","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.bbadis.2013.09.015","article-title":"Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies","volume":"1842","author":"Swomley","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"Suppl 1","key":"10.1016\/j.transci.2021.103164_bib0525","first-page":"S243","article-title":"Oxidative modification of brain proteins in Alzheimer\u2019s disease: perspective on future studies based on results of redox proteomics studies","volume":"33","author":"Sultana","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0530","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3233\/JAD-2011-101425","volume":"24","author":"Sultana","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0535","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archneur.59.5.794","article-title":"Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease","volume":"59","author":"Mecocci","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.transci.2021.103164_bib0540","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000080027","article-title":"Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia","volume":"18","author":"Polidori","year":"2004","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.transci.2021.103164_bib0545","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3233\/JAD-2012-121630","article-title":"Altered levels of homocysteine and serum natural antioxidants links oxidative damage to Alzheimer\u2019s disease","volume":"33","author":"Cankurtaran","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0550","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/gps.1469","article-title":"Decreased plasma antioxidants in patients with Alzheimer\u2019s disease","volume":"21","author":"Kim","year":"2006","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.transci.2021.103164_bib0555","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.bbapap.2011.10.001","article-title":"Circulating biomarkers of protein oxidation for Alzheimer disease: expectations within limits","volume":"1814","author":"Di Domenico","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.transci.2021.103164_bib0560","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/ggi.12361","article-title":"Ischemia-modified albumin and advanced oxidation protein products as potential biomarkers of protein oxidation in Alzheimer\u2019s disease","volume":"15","author":"Altunoglu","year":"2015","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.transci.2021.103164_bib0565","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/10715760802255764","article-title":"Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer\u2019s disease","volume":"42","author":"Greilberger","year":"2008","journal-title":"Free Radic Res"},{"key":"10.1016\/j.transci.2021.103164_bib0570","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.exger.2012.05.019","article-title":"Plasma oxidative stress parameters in men and women with early stage Alzheimer type dementia","volume":"47","author":"Puertas","year":"2012","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.transci.2021.103164_bib0575","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/2251-6581-13-49","article-title":"Glycated albumin: an overview of the in vitro models of an in vivo potential disease marker","volume":"13","author":"Arasteh","year":"2014","journal-title":"J Diabetes Metab Disord"},{"key":"10.1016\/j.transci.2021.103164_bib0580","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cca.2013.07.013","article-title":"Review: glycation of human serum albumin","volume":"425","author":"Anguizola","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.transci.2021.103164_bib0585","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s12020-016-1091-6","article-title":"Glycated albumin: from biochemistry and laboratory medicine to clinical practice","volume":"55","author":"Dozio","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.transci.2021.103164_bib0590","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.biochi.2010.12.003","article-title":"The glycation of albumin: structural and functional impacts","volume":"93","author":"Rondeau","year":"2011","journal-title":"Biochimie"},{"key":"10.1016\/j.transci.2021.103164_bib0595","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1016\/j.bbagen.2013.01.019","article-title":"New insights into deleterious impacts of in vivo glycation on albumin antioxidant activities","volume":"1830","author":"Baraka-Vidot","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.transci.2021.103164_bib0600","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s10895-015-1658-2","article-title":"Oxidative stress mediated cytotoxicity of glycated albumin: comparative analysis of glycation by glucose metabolites","volume":"25","author":"Khan","year":"2015","journal-title":"J Fluoresc"},{"key":"10.1016\/j.transci.2021.103164_bib0605","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.freeradbiomed.2008.06.004","article-title":"Oxidative stresses induced by glycoxidized human or bovine serum albumin on human monocytes","volume":"45","author":"Rondeau","year":"2008","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.transci.2021.103164_bib0610","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3233\/JAD-130914","article-title":"Posttranslational nitro-glycative modifications of albumin in Alzheimer\u2019s disease: implications in cytotoxicity and amyloid-beta peptide aggregation","volume":"40","author":"Ramos-Fernandez","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0615","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3233\/JAD-180243","article-title":"Increased albumin oxidation in cerebrospinal fluid and plasma from Alzheimer\u2019s disease patients","volume":"63","author":"Costa","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0620","doi-asserted-by":"crossref","first-page":"139","DOI":"10.14283\/jpad.2018.48","article-title":"Cross-sectional characterization of albumin glycation state in cerebrospinal fluid and plasma from Alzheimer\u2019s disease patients","volume":"6","author":"Costa","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0625","first-page":"917","article-title":"[Plasmapheresis: its use in multiple sclerosis and other demyelinating processes of the central nervous system. An observation study]","volume":"37","author":"Meca-Lallana","year":"2003","journal-title":"Rev Neurol"},{"key":"10.1016\/j.transci.2021.103164_bib0630","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2021.103164_bib0635","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jca.21266","article-title":"Therapeutic Plasma Exchange in Neurology: 2012","volume":"28","author":"Cortese","year":"2013","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2021.103164_bib0640","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.transci.2014.10.018","article-title":"Therapeutic plasmapheresis in geriatric patients: favorable results","volume":"51","author":"Ataca","year":"2014","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2021.103164_bib0645","first-page":"7","article-title":"Complications in patients treated with plasmapheresis in the intensive care unit","volume":"45","author":"Szczeklik","year":"2013","journal-title":"Anestezjol Intens Ter"},{"key":"10.1016\/j.transci.2021.103164_bib0650","first-page":"149","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-Based approach from the writing committee of the American Society for Apheresis: the seventh special issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2021.103164_bib0655","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1445-5994.1998.tb01952.x","article-title":"Safety of plasmapheresis in the treatment of neurological disease","volume":"28","author":"Vucic","year":"1998","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.transci.2021.103164_bib0660","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3233\/JAD-160565","article-title":"Efficacy and safety of plasma exchange with 5% albumin to modify cerebrospinal fluid and plasma myloid-\u03b2 concentrations and cognition outcomes in Alzheimer\u2019s disease patients: a multicenter, randomized, controlled clinical trial","volume":"56","author":"Boada","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0665","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.trci.2019.01.001","article-title":"Plasma exchange for Alzheimer\u2019s disease management by albumin replacement (AMBAR) trial: study design and progress","volume":"5","author":"Boada","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.transci.2021.103164_bib0670","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/alz.12137","article-title":"A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer\u2019s disease: primary results of the AMBAR Study","volume":"16","author":"Boada","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.transci.2021.103164_bib0675","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1358\/dnp.2009.22.6.1395256","article-title":"Amyloid-targeted therapeutics in Alzheimer\u2019s disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization","volume":"22","author":"Boada","year":"2009","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.transci.2021.103164_bib0680","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3233\/JAD-170693","article-title":"Longitudinal neuroimaging analysis in mild-moderate Alzheimer\u2019s disease patients treated with plasma exchange with 5% human albumin","volume":"61","author":"Cuberas-Borros","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0685","doi-asserted-by":"crossref","first-page":"10417","DOI":"10.1073\/pnas.1834302100","article-title":"Alzheimer\u2019s disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss","volume":"100","author":"Gong","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.transci.2021.103164_bib0690","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.biopsych.2009.01.027","article-title":"Beta amyloid in Alzheimer\u2019s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid","volume":"65","author":"Grimmer","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.transci.2021.103164_bib0695","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3233\/JAD-2012-111139","article-title":"Therapeutic albumin binding to remove amyloid-beta","volume":"29","author":"Costa","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.transci.2021.103164_bib0700","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1471-4159.2002.00889.x","article-title":"Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer\u2019s disease","volume":"81","author":"DeMattos","year":"2002","journal-title":"J Neurochem"},{"key":"10.1016\/j.transci.2021.103164_bib0705","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.1251141","article-title":"Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors","volume":"344","author":"Katsimpardi","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.transci.2021.103164_bib0710","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.cell.2013.04.015","article-title":"Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy","volume":"153","author":"Loffredo","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.transci.2021.103164_bib0715","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1126\/science.1251152","article-title":"Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle","volume":"344","author":"Sinha","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.transci.2021.103164_bib0720","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nm.3569","article-title":"Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice","volume":"20","author":"Villeda","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.transci.2021.103164_bib0725","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1358\/dnp.2009.22.6.1395256","article-title":"Amyloid-targeted therapeutics in Alzheimer\u2019s disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization","volume":"22","author":"Boada","year":"2009","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.transci.2021.103164_bib0730","first-page":"S4","article-title":"AMBAR (Alzheimer\u2019s Management By Albumin Replacement) Phase 2B\/3 Trial: complete clinical, biomarker and neuroimaging results","volume":"6","author":"Paez","year":"2019","journal-title":"J Prev Alzheimers Dis"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050221001300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050221001300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:51:32Z","timestamp":1761468692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050221001300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":146,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1473050221001300"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2021.103164","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging insights into the role of albumin with plasma exchange in Alzheimer\u2019s disease management","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2021.103164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103164"}}